The field of pulmonary hypertension has been transformed beyond recognition over the past
30 years. Advances in the understanding of pathophysiology has led to the testing of …

Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …

Over the past 20 years, more than ten vasoactive drugs have been developed and
commercialised for the management of pulmonary arterial hypertension (PAH). As per initial …

Research and treatment of pulmonary vascular diseases pose distinct challenges. Despite
these hurdles (or perhaps because of them), a cadre of basic scientists, geneticists …

Until 20 years ago the treatment of pulmonary arterial hypertension (PAH) was based on
case reports and small series, and was largely ineffectual. As a deeper understanding of the …

Persistent challenges in managing pulmonary vascular disease progression and poor
outcomes, despite the aggressive use of current drug therapies, highlight the need for …

In a remarkably short interval of time, pulmonary artery hypertension (PAH) has evolved from
a disease of unknown pathogenesis devoid of effective therapy to a condition whose cellular …

We have witnessed significant advances in the management of pulmonary arterial
hypertension (PAH)(1), a rare and severe condition characterized by intense pulmonary …

Marius M Hoeper and colleagues, 1 which highlights a unique group of patients with
pulmonary hypertension who meet the diagnostic criteria for group 1 pulmonary arterial …

While there have been advances in the field of pulmonary arterial hypertension (PAH),
disease management remains suboptimal for many patients. The development of novel …